Navigation Links
Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
Date:3/27/2009

SAN FRANCISCO, March 27 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a leading company in the development of novel therapeutics for heart failure patients, announced today that, in the course of reviewing the Investigational New Drug (IND) application materials that Nile submitted to the U.S. Food and Drug Administration (FDA) to support the initiation of the Company's Phase IIb clinical trial with CD-NP for the treatment of acute heart failure, the FDA has placed CD-NP on clinical hold. In a letter sent to the Company this week and in a follow-up teleconference with the Company, the FDA requested additional data from the recently completed Phase IIa clinical trial and modifications to CD-NP's Investigator Brochure (IB). The Company is working diligently to respond in a timely manner and expects to be able to provide a complete response to the FDA's requests with recently finalized data from the Phase IIa clinical trial in acute heart failure patients.

About CD-NP

CD-NP is a novel chimeric natriuretic peptide in clinical development for the treatment of acute heart failure. CD-NP was designed to have direct hemodynamic and renal activity to reduce symptoms of dyspnea, be diuretic and natriuretic and preserve or enhance renal function in heart failure patients. In addition to an initial indication for acute heart failure, CD-NP has potential utility in other indications which include preservation of cardiac function subsequent to acute myocardial infarction (AMI), and prevention of renal damage subsequent to cardiac surgery.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing it
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
2. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
5. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
6. Cell Therapeutics Announces Filing of Form 10-K
7. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... State University have developed a technique for controlling the ... voltages, opening the door to a new generation of ... hinges on the fact that the oxide "skin" of ... acts as a surfactant, lowering the surface tension ... researchers used a liquid metal alloy of gallium and ...
(Date:9/15/2014)... interdisciplinary team of researchers led by Northeastern University ... precise inter-nanotube junctions and a variety of nanocarbon ... facile and easily scalable, which will allow the ... networks for use in applications ranging from electronic ... from cars to sports equipment. , Their findings ...
(Date:9/15/2014)... , Sept. 15, 2014  iVinci Health LLC, ... comprehensive Patient Revenue Management system, branded as VisitPay®, has ... also announced the launch of a new extension to ... provides an easy and convenient way for patients to ... balances owed by them and their families. ...
(Date:9/15/2014)... Applied Silicone Corporation, a global ... medical device and critical healthcare market, introduces a ... medical device market. The Dual Matrix Gel ... silicone gel with improved fracture resistance, cohesive strength, ... of two crosslinked networks working in conjunction to ...
Breaking Biology Technology:Researchers control surface tension to manipulate liquid metals 2Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2
... Stock for Rights to Spinal Cells in Future, ... (Amex: CUR ), announces that Korean conglomerate, CJ,CheilJedang ... for the exclusive license to Neuralstem,s stem cell-products and,technology ... part of the agreement, CJ has purchased $2.5 million ...
... will support Phase 3 Trials for Crohn,s Disease, Pouchitis and ... ... 20 Ocera Therapeutics, a,biopharmaceutical company focused on the licensing, ... of,gastrointestinal and liver diseases, has announced the completion of a,$35.5 ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today ... Pharmaceuticals GmbH (Merz) for sales,by Merz and its ... Alzheimer,s disease for the quarter ended September 30,2007. ... royalty payments on sales of Memantine by Merz ...
Cached Biology Technology:Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation 2Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation 3Ocera Therapeutics Closes $35.5 Million Series C Financing 2Ocera Therapeutics Closes $35.5 Million Series C Financing 3Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine 2
(Date:9/15/2014)... cognitive function may play roles in one,s musical aptitude, ... timbre, tone durations, and formal structure in music. , ... that extremes in musical aptitude (extreme capacity/no capacity) are ... having moderate aptitude. , "This is a typical feature ... and it is influenced to varying degrees by environmental ...
(Date:9/15/2014)... is no published account where hippopotamuses are demonstrably shown ... of water. But if they can,t swim, how did ... widely accepted models for the methods, patterns, and timing ... Cyprus, Crete, and Madagascar) may need to be reconsidered. ... the mainland are not currently supported by positive ...
(Date:9/15/2014)... is available in German . ... is straightforward: it doubles, divides in the middle and ... long assumed that cells of the same kind are ... Bulgheresi,s team, University of Vienna, revealed that two non-model ... perceivable by the naked eye. These findings have been ...
Breaking Biology News(10 mins):Think big! Bacteria breach cell division size limit 2
... A new study suggests that jewel scarab beetles find ... that creates the 3D effects for the blockbuster movie ... Texas, the jewel scarab species Chrysina gloriosa ... ability could provide the beetles with a tremendous advantage, ...
... Lovn Centre for Marine Sciences at the University of Gothenburg ... in the Gullmarsfjord north of Gothenburg. The bacterium has been ... marine research center. Researcher Matthias Obst from the ... at the Sven Lovn Centre for Marine Sciences, a new ...
... Boston, MA A tobacco company,s new, dissolvable ... but which in some cases resembles popular candies--could lead ... new study from the Harvard School of Public Health ... for Disease Control and Prevention (CDC) and the Food ...
Cached Biology News:Beetles stand out using 'Avatar' tech 2Tobacco company's new, dissolvable nicotine products could lead to accidental poisoning 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Biology Products: